Status:
COMPLETED
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Lead Sponsor:
National Eye Institute (NEI)
Conditions:
AMD
Eligibility:
All Genders
50+ years
Brief Summary
Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the United States. Currently, there is no safe way to obtain cells from the eye to study. But researchers now c...
Detailed Description
Objective: This ancillary study will establish a repository of biospecimens to generate induced pluripotent stem (iPS) cells that can be differentiated into ocular cell types, to be used for study of ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- To be eligible, the following inclusion criteria must be met, where applicable.
- AREDS2 participants who have provided DNA samples. A list will be generated based upon the results, picking the top GWAS results from this cohort.
- Participant must understand and sign the protocol s informed consent document.
- Participant is able to provide 20 ml blood sample.
- EXCLUSION CRITERIA:
- A participant is not eligible if any of the following exclusion criteria are present.
- 1\. Participant is unable to comply with study procedures.
Exclusion
Key Trial Info
Start Date :
May 23 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 21 2019
Estimated Enrollment :
187 Patients enrolled
Trial Details
Trial ID
NCT03372746
Start Date
May 23 2018
End Date
March 21 2019
Last Update
April 5 2019
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina-Vitreous Associates Med Group
Beverly Hills, California, United States, 90211
2
Bascom Palmer Eye Institute
Miami, Florida, United States, 33136
3
Emory University Eye Center
Atlanta, Georgia, United States, 30322
4
Retina Vitreous Associates of Kentucky
Lexington, Kentucky, United States, 40509